HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

3- amino- 4- (2- dimethylaminomethylphenylsulfanyl)benzonitrile

a serotonin transporter antagonist; structure in first source
Also Known As:
(11C)DASB; 3-amino-4-(N-methyl-N-(11C)methyl-aminomethylphenylsulfanyl)benzonitrile; 3-amino-4-diMeNMePhS-BzCN
Networked: 29 relevant articles (2 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Ichise, Masanori: 4 articles (01/2010 - 08/2006)
2. Smit, Marenka: 2 articles (01/2022 - 01/2018)
3. Vállez García, David: 2 articles (01/2022 - 01/2018)
4. de Jong, Bauke M: 2 articles (01/2022 - 01/2018)
5. Becker, Georg-Alexander: 2 articles (01/2021 - 12/2020)
6. Hesse, Swen: 2 articles (01/2021 - 12/2020)
7. Kim, Hang-Keun: 2 articles (01/2021 - 01/2017)
8. Kim, Jeong-Hee: 2 articles (01/2021 - 01/2017)
9. Kim, Jong-Hoon: 2 articles (01/2021 - 01/2017)
10. Luthardt, Julia: 2 articles (01/2021 - 12/2020)

Related Diseases

1. Alzheimer Disease (Alzheimer's Disease)
2. Premature Ejaculation
3. Schizophrenia (Dementia Praecox)
4. Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive)
5. Parkinson Disease (Parkinson's Disease)
01/01/2019 - "Compared with healthy controls, premotor A53T SNCA carriers showed loss of [11C]DASB non-displaceable binding potential in the ventral (p<0·0001) and dorsal (p=0·0002) raphe nuclei, caudate (p=0·00015), putamen (p=0·036), thalamus (p=0·00074), hypothalamus (p<0·0001), amygdala (p=0·0041), and brainstem (p=0·046); and in A53T SNCA carriers with Parkinson's disease this loss was extended to the hippocampus (p=0·0051), anterior (p=0·022) and posterior cingulate (p=0·036), insula (p=0·0051), frontal (p=0·0016), parietal (p=0·019), temporal (p<0·0001), and occipital (p=0·0053) cortices. "
01/01/2018 - "Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET."
01/01/2018 - "Higher severity of sleep symptoms (assessed with Parkinson Disease Sleep Scale) correlated with lower [11C]DASB binding in caudate (r = 0.77; P < 0.001), putamen (r = 0.84; P < 0.001), ventral striatum (r = 0.86; P < 0.001), thalamus (r = 0.79; P < 0.001), hypothalamus (r = 0.90; P < 0.001) and raphe nuclei (r = 0.83; P < 0.001). "
01/01/2019 - "Premotor A53T SNCA carriers had loss of [11C]DASB non-displaceable binding potential in brain areas corresponding to Braak stages 1-3, whereas [11C]DASB non-displaceable binding potential was largely preserved in areas corresponding to Braak stages 4-6. Except for one participant who was diagnosed with Parkinson's disease in the past year, all A53T SNCA carriers with Parkinson's disease had decreases in [11C]DASB non-displaceable binding potential in brain areas corresponding to Braak stages 1-6. Decreases in [11C]DASB non-displaceable binding potential in the brainstem were associated with increased Movement Disorder Score-Unified Parkinson's Disease Rating Scale total scores in all A53T SNCA carriers (r -0·66, 95% CI -0·88 to -0·20; p=0·0099), idiopathic Parkinson's disease cohort 1 (r -0·66, -0·84 to -0·36; p=0·00031), and idiopathic Parkinson's disease cohort 2 (r -0·71, -0·84 to -0·52; p<0·0001). "
09/15/2008 - "Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB."

Related Drugs and Biologics

1. Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)
2. Serotonin (5 Hydroxytryptamine)
3. 5-HT2A Serotonin Receptor (5 HT2A Receptor)
4. Ligands
5. DA 8031
6. benzylamine
7. Antipsychotic Agents (Antipsychotics)
8. Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
9. Glucose (Dextrose)
10. Escitalopram